EVALUATION OF THE EFFECTS OF REPEAT DOSE DABRAFENIB ON THE SINGLE DOSE PK OF AN OATP1B1/1B3 AND CYP3A4 SUBSTRATE.

被引：0
|
作者：
Nebot, N. [1 ]
Won, C. [2 ]
Moreno, V. [3 ]
Munoz-Couselo, E. [4 ]
Lee, D-Y. [1 ]
Huang, Y. [5 ]
Bouillaud, E. [6 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Novartis Inst Biomed Res, E Hanover, NJ USA
[3] START Madrid FJD Hosp Fdn Jimenez Diaz, Madrid, Spain
[4] Vall Hebron Hosp, Barcelona, Spain
[5] Ascentage Pharma, Rockville, MD USA
[6] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-102
引用
收藏
页码：S82 / S82
页数：1
相关论文
共 50 条
  • [1] Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
    Nebot, Noelia
    Won, Christina S.
    Moreno, Victor
    Munoz-Couselo, Eva
    Lee, Dung-Yang
    Gasal, Eduard
    Bouillaud, Emmanuel
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (09): : 1054 - 1063
  • [2] Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
    Cardona, Panli
    Dutta, Sandeep
    Houk, Brett
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (07): : 810 - 818
  • [3] VARIABILITY OF OATP1B1/1B3 IN VITRO INHIBITION CONSTANTS AND THE RESULTING IMPACT ON CLINICAL EVALUATION
    McFeely, Savannah
    Ritchie, Tasha
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S94 - S94
  • [4] Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1
    Annaert, P.
    Ye, Z. W.
    Stieger, B.
    Augustijns, P.
    XENOBIOTICA, 2010, 40 (03) : 163 - 176
  • [5] Cellular uptake of rose bengal is mediated by OATP1B1/1B3 transporters
    Sztandera, K.
    Gorzkiewicz, M.
    Zizzi, E. A.
    Dybczak, N.
    Poltorak, L.
    Deriu, M. A.
    Klajnert-Maculewicz, B.
    BIOELECTROCHEMISTRY, 2023, 152
  • [6] The impact of short-term cyp3a4/oatp1b1/oatp1b3 inhibitors on persistence with statin treatment: a case crossover study
    Wiid, Z.
    Bennett, K.
    Barron, I.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) : 673 - 673
  • [7] Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions
    Mochizuki, Tatsuki
    Zamek-Gliszczynski, Maciej J.
    Yoshida, Kenta
    Mao, Jialin
    Taskar, Kunal
    Hirabayashi, Hideki
    Chu, Xiaoyan
    Lai, Yurong
    Takashima, Tadayuki
    Rockich, Kevin
    Yamaura, Yoshiyuki
    Fujiwara, Kaku
    Mizuno, Tadahaya
    Maeda, Kazuya
    Furihata, Kenichi
    Sugiyama, Yuichi
    Kusuhara, Hiroyuki
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (06) : 1315 - 1323
  • [8] Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s
    Sun, Xiaolin
    Li, Junxiu
    Guo, Chaorui
    Xing, Han
    Xu, Jie
    Wen, Yanli
    Qiu, Zhixia
    Zhang, Qiuyang
    Zheng, Yi
    Chen, Xijing
    Zhao, Di
    DRUG METABOLISM AND PHARMACOKINETICS, 2016, 31 (04) : 269 - 275
  • [9] Importance of OATP1B1 and 1B3 in the Liver Uptake of Luteolin and Its Consequent Glucuronidation Metabolites
    Zhi, Hui
    Yuan, Yuan
    Zhang, Chunzhen
    Jiang, Yiguo
    Zhang, Hongjian
    Wang, Cheng
    Ruan, Jianqing
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2020, 68 (07) : 2063 - 2070
  • [10] OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture
    Ulvestad, Maria
    Bjorquist, Petter
    Molden, Espen
    Asberg, Anders
    Andersson, Tommy B.
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (09) : 1219 - 1226
12345